Spon­sors should flag de­cen­tral­ized as­pects of can­cer tri­als to prep for the post-Covid era, FDA says

As more and more clin­i­cal tri­als dur­ing the pan­dem­ic have har­nessed the pow­er of re­mote as­sess­ments and mod­i­fi­ca­tions, the FDA On­col­o­gy Cen­ter of Ex­cel­lence and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER